New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareIGF-1 LR3 vs Orforglipron

IGF-1 LR3 vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
IGF-1 LR3
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
20–30 hours
~12 hours (once-daily oral dosing)
Admin Route
SubQ, IM
Oral
Research
Typical Dose
40–80 mcg
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Once daily or split twice daily
Once daily
Key Benefits
  • Direct muscle hypertrophy via IGF-1R stimulation
  • Muscle hyperplasia (new fiber formation) — unique among peptides
  • Rapid gains in lean muscle mass
  • Accelerated recovery from training and injury
  • Increased nutrient uptake by muscle cells
  • Fat oxidation enhancement
  • Bone density improvement
  • Cartilage and connective tissue repair
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Hypoglycemia (significant risk — insulin-like activity)
  • Acromegaly-like effects with excessive long-term use
  • Jaw and hand swelling
  • Organ hypertrophy with extreme doses
  • +2 more
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With